Disclaimer: For the use of registered Medical practitioner or research lab
Virulina also, by inhibiting RNA polymerase in COVID 19 viral cells, inhibits the replication of Viral RNA.The anti viral study conducted at Regional Centre of Biotechnolofy clearly concludes that Virulina is a promising candidate for treatment in covid-19.
VIRULINA has shown by preclinical studies, an increase in the early and delayed hypersensitivity reaction to immunogenicity induciers and has a stimulatory effect on chemotaxis dependent leucocyte migration and Proliferation of Lymphocyte, establishing it as an immunomodulator.
VIRULINA in preclinical studies, also enhances the phagocytic efficacy of the PMN cells against infecting microbial cells, thereby stimulating a non-specific immune response.
VIRULINA may alleviate poly(I:C)-induced inflammation by decreasing levels of inflammatory mediators, such as Nitric Oxide, cytokines, chemokines, and growth factors, in RAW 264.7 mouse macrophages and is thus a candidate for modulating virus-hyperinflammation such as a cytokine storm, in COVID 19 infections, and has a significant mucolytic and fibrinolytic activity.
* For any further information please write to us on email: info@virulina.com